Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Pipeline Review, H1 2016
Summary
Global Markets Directs, Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Pipeline Review, H1 2016, provides in depth analysis on Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted pipeline therapeutics.
The report provides comprehensive information on the Somatostatin Receptor Type 2 (SRIF-1 or SSTR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF-1 or SSTR2)
- The report reviews Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF-1 or SSTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) Overview 7
Therapeutics Development 8
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Products under Development by Stage of Development 8
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Products under Development by Therapy Area 9
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Products under Development by Indication 10
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Products under Development by Companies 13
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Products under Development by Universities/Institutes 15
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Companies Involved in Therapeutics Development 24
Boehringer Ingelheim GmbH 24
Crinetics Pharmaceuticals, Inc. 25
Ipsen S.A. 26
OctreoPharm Sciences GmbH 27
Progenics Pharmaceuticals, Inc. 28
Sompharmaceuticals S.A. 29
Strongbridge Biopharma plc 30
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Drug Profiles 31
BIM-23A758 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
COR-005 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Edotreotide Labeled Yttrium 90 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
FX-125L - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
G-02113 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
lanreotide acetate - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
OPS-201 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Agonize SSTR4 and SSTR2 for Chronic Pain and Neuropathic Pain - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Synthetic Peptide to Antagonize Somatostatin Receptor Type 2 for Neuroendocrine Tumors - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Dormant Projects 47
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Discontinued Products 50
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Featured News & Press Releases 51
Oct 15, 2015: Ipsen Announces Eight Studies of Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society Symposium 51
Oct 06, 2015: Health Canada Approves Somatuline Autogel (lanreotide) Injection for the treatment of enteropancreatic neuroendocrine tumours 51
May 14, 2015: Ipsen Announces Data Presentations for Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting 52
Apr 27, 2015: Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain 53
Apr 14, 2015: MHRA approves Ipsens Somatuline (lanreotide) Autogel 120mg as a new treatment for gastroenteropancreatic tumours 54
Jan 13, 2015: Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline Depot (lanreotide), at Gastrointestinal Cancers Symposium 54
Dec 16, 2014: Ipsens Somatuline Depot is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors 55
Nov 06, 2014: Ipsen Announces FDA Approval of a New Delivery Device for Somatuline Depot (lanreotide) Injection 57
Sep 01, 2014: Ipsen Announces Acceptance of Filings for Somatuline in the Treatment of GEP-NET1s in the US with Priority Review and in Europe 58
Jul 16, 2014: New England Journal of Medicine Publishes Ipsens Somatuline CLARINET Phase III Results in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors 58
Jul 01, 2014: Ipsen submits marketing authorization applications in the US and Europe for Somatuline (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors 60
Apr 22, 2014: Aspireo Reports Data in Further Phase Ib Study 60
Jan 22, 2014: Ipsen Implements a New Governance in the United States to Prepare for the Launch of Somatuline in Oncology 61
Jan 17, 2014: Ipsen announces at ASCO GI that ELECT clinical trial of Somatuline in the control of symptoms in GEP-NET1 patients with carcinoid syndrome met its primary endpoint 61
Jan 14, 2014: Ipsen to set up its own US oncology team for Somatuline Depot Injection in neuroendocrine tumors 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65
List Of Tables
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Stage and Mechanism of Action, H1 2016 19
Number of Products by Stage and Route of Administration, H1 2016 21
Number of Products by Stage and Molecule Type, H1 2016 23
Pipeline by Boehringer Ingelheim GmbH, H1 2016 24
Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016 25
Pipeline by Ipsen S.A., H1 2016 26
Pipeline by OctreoPharm Sciences GmbH, H1 2016 27
Pipeline by Progenics Pharmaceuticals, Inc., H1 2016 28
Pipeline by Sompharmaceuticals S.A., H1 2016 29
Pipeline by Strongbridge Biopharma plc, H1 2016 30
Dormant Projects, H1 2016 47
Dormant Projects (Contd..1), H1 2016 48
Dormant Projects (Contd..2), H1 2016 49
Discontinued Products, H1 2016 50
List Of Figures
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Top 10 Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy/Combination Products, H1 2016 17
Number of Products by Mechanism of Actions, H1 2016 18
Number of Products by Stage and Mechanism of Actions, H1 2016 18
Number of Products by Routes of Administration, H1 2016 20
Number of Products by Stage and Routes of Administration, H1 2016 20
Number of Products by Molecule Types, H1 2016 22
Number of Products by Stage and Molecule Type, H1 2016 22
